Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [8].

Core Insights - Sarepta Therapeutics has stabilized after a tumultuous period and is now available at a historic discount, presenting a potential buying opportunity for investors [1] - The company has strong patient support and has reached a resolution, indicating positive developments in its operations [1] Investment Strategy - The focus is on a long/short equity strategy in small to mid-cap biotech, emphasizing thorough modeling for new drugs [1] - There is a search for de-risked but overlooked assets, suggesting a strategic approach to identifying investment opportunities [1]

Core Viewpoint - A securities class-action lawsuit has been initiated against Sarepta Therapeutics due to safety concerns and regulatory setbacks related to its gene therapy, ELEVIDYS, alleging that the company misled investors about the treatment's safety and efficacy [1]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta misrepresented ELEVIDYS as a safe and effective treatment with a clear path to regulatory approval [1]. - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, with a deadline for investors to serve as Lead Plaintiff set for August 25, 2025 [2]. - Hagens Berman is investigating claims on behalf of investors who suffered substantial losses and is encouraging those with knowledge of the situation to come forward [4]. Group 2: Regulatory Challenges - European regulators have rejected ELEVIDYS, with the European Medicines Agency (EMA) stating that a trial involving 125 children showed no significant improvement in movement for patients receiving the therapy compared to those receiving a placebo [3]. - The EMA's decision significantly impacts Sarepta's plans to expand in the European market and raises concerns about the effectiveness and safety of gene therapies [3]. Group 3: Timeline of Events - Key events leading to the lawsuit include a patient death in an ELEVIDYS trial reported on March 18, 2025, and a second patient death from acute liver failure on June 15, 2025, which led to the suspension of shipments for certain patient groups [6]. - The FDA issued a safety communication on June 24, 2025, confirming its investigation into the risk of acute liver failure associated with ELEVIDYS [6]. Group 4: Investigation and Whistleblower Information - Hagens Berman is actively seeking information from whistleblowers who may have non-public information regarding Sarepta, with potential rewards for original information provided to the SEC [5].

To join the Sarepta class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. Allegations Against Sarepta Therapeutics - The complaint alleges that Sarepta Therapeutics made materially false and/or misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [3]. - Specific allegations include: - ELEVIDYS poses significant safety risks to patients [3]. - The trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Next Steps for Shareholders - Shareholders are advised to register for the class action by August 25, 2025, to participate in the case [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=162487&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaint ...

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure after receiving Elevidys, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 on March 17, 2025, to $73.54 on March 18, 2025 [4]. - After a second patient death was reported on June 15, 2025, Sarepta's stock fell by $15.24, or more than 42%, from $36.18 on June 13, 2025, to $20.94 on June 16, 2025 [4]. - A third patient death related to Elevidys was reported on July 17, 2025, leading to a further decline of over 40% in the stock price on July 18, 2025 [5]. Legal Context - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2].

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv- 05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta's exe ...

Core Viewpoint - A securities class-action lawsuit has been initiated against Sarepta Therapeutics due to safety concerns and regulatory setbacks related to its gene therapy, ELEVIDYS, alleging that the company misled investors about the treatment's safety and efficacy [1]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta misrepresented ELEVIDYS as a safe and effective treatment with a clear path to regulatory approval [1]. - The class period for the lawsuit is defined as June 22, 2023, to June 24, 2025, with a deadline for investors to serve as Lead Plaintiff set for August 25, 2025 [2]. - The lawsuit highlights a timeline of disclosures and stock price declines linked to the drug's safety issues [2]. Group 2: Regulatory Challenges - European regulators have rejected ELEVIDYS, with the European Medicines Agency (EMA) stating that a trial involving 125 children showed no significant improvement in movement for patients receiving the therapy compared to those on a placebo [3]. - This rejection significantly impacts Sarepta's plans to expand in the European market and raises concerns about the effectiveness and safety of gene therapies [3]. Group 3: Investigation and Responses - Hagens Berman is investigating claims on behalf of investors who experienced substantial losses, encouraging individuals with relevant information to come forward [4]. - Reed Kathrein, a partner at Hagens Berman, noted that Sarepta's stock has been adversely affected by safety and regulatory news, particularly following the EMA's rejection of ELEVIDYS [5]. - The firm is also looking into whether Sarepta's previous statements and clinical trial protocols adequately reflected the risks associated with the drug [5]. Group 4: Timeline of Events - Key events leading to the lawsuit include a patient death reported on March 18, 2025, followed by an EU review that halted some clinical studies [6]. - A second patient death from acute liver failure was reported on June 15, 2025, leading to the suspension of shipments for certain patient groups [6]. - On June 24, 2025, the FDA confirmed its investigation into the risk of acute liver failure associated with ELEVIDYS [6].